Interessante Sache:
Tiziana Life Sciences plans phase II trials of nasal antibody treatment in COVID-19 patients
Foralumab may be effective in treating new coronavirus variants from the UK, Brazil and South Africa, the company said It is the first and only monoclonal antibody that can be dosed nasally or orally An earlier study revealed evidence the drug reduced pulmonary and systemic inflammation and was well tolerated
Tiziana Life Sciences PLC -
Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) is taking its nasally-administered monoclonal antibody (mAB) into phase II clinical trials in people with moderate to severe Coronavirus (COVID-19).
This follows an earlier study in Brazil, which showed evidence that Foralumab reduced pulmonary and systemic inflammation and was well tolerated. Nasally-administered Foralumab is thought to work by improving the immune system by stimulating the body’s regulatory T cells.
It is also believed to dampen harmful T cell responses in the nasal and respiratory tract, the primary sites of the COVID-19 virus. |